ANCA-Associated Vasculitis, Anti-GBM Disease, Lupus Nephritis
View More View Less
  • 1 Centre for Inflammatory Disease, Imperial College London, London, United Kingdom
  • 2 Imperial College Healthcare NHS Trust, London, United Kingdom
  • 3 Centre for Inflammatory Disease, Imperial College London, London, United Kingdom
  • 4 Imperial College Healthcare NHS Trust, London, United Kingdom
  • 1.

    Jennette JC, Falk RJ: Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 10: 463473, 2014 PubMed

  • 2.

    Jennette JC: Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 17: 603606, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Available at: https://kdigo.org/guidelines/gn/. Accessed October 6, 2020

    • Search Google Scholar
    • Export Citation
  • 4.

    Ntatsaki E, Carruthers D, Chakravarty K, D’Cruz D,L, Jayne D, ; BSR and BHPR Standards, Guidelines and Audit Working Group: BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 53: 23062309, 2014 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, : EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75: 15831594, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Suárez LF, Guillevin L, : Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 13: 683692, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Moiseev S, Cohen Tervaert JW, Arimura Y, Bogdanos DP, Csernok E, Damoiseaux J, : 2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev 19: 102618, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    O’Reilly VP, Wong L, Kennedy C, Elliot LA, O’Meachair S, Coughlan AM, : Urinary soluble CD163 in active renal vasculitis. J Am Soc Nephrol 27: 29062916, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Moran SM, Monach PA, Zgaga L, Cuthbertson D, Carette S, Khalidi NA, : Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant 35: 283291, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 10.

    Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, : Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21: 16281636, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    van Daalen EE, Wester Trejo MAC, Göçeroğlu A, Ferrario F, Joh K, Noël LH, : Developments in the histopathological classification of ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol 15: 11031111, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Brix SR, Noriega M, Tennstedt P, Vettorazzi E, Busch M, Nitschke M, : Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int 94: 11771188, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, : Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 24612469, 2005 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, ; EUVAS investigators: Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up. Ann Rheum Dis 71: 955960, 2012 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, ; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221232, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, ; European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211220, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, ; European Vasculitis Study Group (EUVAS): Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: A randomised, non-inferiority trial. Ann Rheum Dis 78: 399405, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Tuin J, Stassen PM, Bogdan DI, Broekroelofs J, van Paassen P, Cohen Tervaert JW, : Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: Randomized, controlled trial. Clin J Am Soc Nephrol 14: 10211028, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Walsh M, Catapano F, Szpirt W, Thorlund K, Bruchfeld A, Guillevin L, : Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: A meta-analysis. Am J Kidney Dis 57: 566574, 2011 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Walters GD, Willis NS, Cooper TE, Craig JC: Interventions for renal vasculitis in adults. Cochrane Database Syst Rev 1: CD003232, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 21.

    Walsh M, Merkel PA, Peh CA, Szpirt WM, Puéchal X, Fujimoto S, ; PEXIVAS Investigators: Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382: 622631, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22.

    Cortazar FB, Muhsin SA, Pendergraft WF 3rd, Wallace ZS, Dunbar C, Laliberte K, : Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis. Kidney Int Rep 3: 394402, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    McAdoo SP, Medjeral-Thomas N, Gopaluni S, Tanna A, Mansfield N, Galliford J, : Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant 34: 6373, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    Pepper RJ, McAdoo SP, Moran SM, Kelly D, Scott J, Hamour S, : A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 58: 260268, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 25.

    Walsh M, Merkel PA, Mahr A, Jayne D: Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken) 62: 11661173, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    Chen M, Jayne DRW, Zhao MH: Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat Rev Nephrol 13: 359367, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27.

    Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, ; CLEAR Study Group: Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 28: 27562767, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, ; European Vasculitis Study Group: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349: 3644, 2003 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, ; European Vasculitis Study Group (EUVAS): Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial. JAMA 304: 23812388, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Karras A, Pagnoux C, Haubitz M, Groot K, Puechal X, Tervaert JWC, ; European Vasculitis Society: Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76: 16621668, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, ; French Vasculitis Study Group: Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371: 17711780, 2014 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32.

    Terrier B, Pagnoux C, Perrodeau É, Karras A, Khouatra C, Aumaître O, ; French Vasculitis Study Group: Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis 77: 11501156, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33.

    Charles P, Terrier B, Perrodeau É, Cohen P, Faguer S, Huart A, ; French Vasculitis Study Group: Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77: 11431149, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 34.

    van Dam LS, Dirikgil E, Bredewold EW, Ray A, Bakker JA, van Kooten C, : Proteinase-3-anti-neutrophil cytoplasmic antibodies (PR3-ANCAs) predict relapses in ANCA-associated vasculitis patients after rituximab [published online ahead of print June 30, 2020]. Nephrol Dial Transplant doi: 10.1093/ndt/gfaa066.2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35.

    Tieu J, Smith R, Basu N, Brogan P, D’Cruz D, Dhaun N, : Rituximab for maintenance of remission in ANCA-associated vasculitis: Expert consensus guidelines. Rheumatology (Oxford) 59: e24e32, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36.

    Wallace ZS, Fu X, Harkness T, Stone JH, Zhang Y, Choi H: All-cause and cause-specific mortality in ANCA-associated vasculitis: Overall and according to ANCA type. Rheumatology (Oxford) 59: 23082315, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37.

    Tan JA, Dehghan N, Chen W, Xie H, Esdaile JM, Avina-Zubieta JA: Mortality in ANCA-associated vasculitis: A meta-analysis of observational studies. Ann Rheum Dis 76: 15661574, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 38.

    Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, ; European Vasculitis Study Group: Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70: 488494, 2011 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39.

    McGovern D, Williams SP, Parsons K, Farrah TE, Gallacher PJ, Miller-Hodges E, : Long-term outcomes in elderly patients with ANCA-associated vasculitis. Rheumatology (Oxford) 59: 10761083, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40.

    Waki D, Nishimura K, Tokumasu H, Kadoba K, Mukoyama H, Saito R, : Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study. Medicine (Baltimore) 99: e19173, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41.

    Weiner M, Goh SM, Mohammad AJ, Hruskova Z, Tanna A, Bruchfeld A, : Outcome and treatment of elderly patients with ANCA-associated vasculitis. Clin J Am Soc Nephrol 10: 11281135, 2015 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42.

    McAdoo SP, Pusey CD: Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol 12: 11621172, 2017 PubMed

  • 43.

    Canney M, O’Hara PV, McEvoy CM, Medani S, Connaught DM, Abdalla AA, : Spatial and temporal clustering of anti-glomerular basement membrane disease. Clin J Am Soc Nephrol 11: 13921399, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 44.

    Gu QH, Xie LJ, Jia XY, Ma R, Liao YH, Cue Z, : Fever and prodromal infections in anti-glomerular basement membrane disease. Nephrology (Carlton) 23: 476482, 018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45.

    Prendecki M, Clarke C, Cairns T, Cook T, Roufosse C, Thomas D, : Anti-glomerular basement membrane disease during the COVID-19 pandemic. Kidney Int 98: 780781, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 46.

    Ooi JD, Chang J, O’Sullivan KM, Pedchenko V, Hudson BG, Vandenbark AA, : The HLA-DRB1*15:01-restricted Goodpasture’s T cell epitope induces GN. J Am Soc Nephrol 24: 419431, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 47.

    Ooi JD, Petersen J, Tan YH, Huynh M, Willett ZJ, Ramarathinam SH, : Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. Nature 545: 243247, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 48.

    Huart A, Josse AG, Chauveau D, Korach JM, Heshmati F, Bauvin E, ; French Society of Hemapheresis: Outcomes of patients with Goodpasture syndrome: A nationwide cohort-based study from the French Society of Hemapheresis. J Autoimmun 73: 2429, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 49.

    Marques C, Carvelli J, Biard L, Faguer S, Provôt F, Matignon M, : Prognostic factors in anti-glomerular basement membrane disease: A multicenter study of 119 patients. Front Immunol 10: 1665, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 50.

    van Daalen EE, Jennette JC, McAdoo SP, Pusey CD, Alba MA, Poulton CJ, : Predicting outcome in patients with anti-GBM glomerulonephritis. Clin J Am Soc Nephrol 13: 6372, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 51.

    Yang R, Otten MA, Hellmark T, Collin M, Björck L, Zhao MH, : Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes. Nephrol Dial Transplant 25: 24792486, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 52.

    Soveri I, Mölne J, Uhlin F, Nilsson T, Kjellman C, Sonesson E, : The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease. Kidney Int 96: 12341238, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 53.

    McAdoo SP, Tanna A, Hrušková Z, Holm L, Weiner M, Arulkumaran N, : Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 92: 693702, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 54.

    McCall AS, Bhave G, Pedchenko V, Hess J, Free M, Little DJ, : Inhibitory anti-peroxidasin antibodies in pulmonary-renal syndromes. J Am Soc Nephrol 29: 26192625, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 55.

    Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, ; American College of Rheumatology: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64: 797808, 2012 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 56.

    Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D’Cruz D, ; British Society for Rheumatology Standards, Audit and Guidelines Working Group: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford) 57: e1e45, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 57.

    Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, : 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79: 713723, 2020 PubMed

    • Search Google Scholar
    • Export Citation
  • 58.

    Almaani S, Meara A, Rovin BH: Update on lupus nephritis. Clin J Am Soc Nephrol 12: 825835, 2017 PubMed

  • 59.

    Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C: Lupus nephritis. Nat Rev Dis Primers 6: 7, 2020 PubMed

  • 60.

    Stojan G, Petri M: Epidemiology of systemic lupus erythematosus: An update. Curr Opin Rheumatol 30: 144150, 2018 PubMed

  • 61.

    Maningding E, Dall'Era M, Trupin L, Murphy LB, Yazdany J. Racial and ethnic differences in the prevalence and time to onset of manifestations of systemic lupus erythematosus: The California Lupus Surveillance Project. Arthritis Care Res (Hoboken) 72: 622629, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 62.

    Moroni G, Vercelloni PG, Quaglini S, Gatto M, Gianfreda D, Sacchi L, : Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis 77: 13181325, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 63.

    Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, : Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 93: 789796, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 64.

    Malvar A, Pirruccio P, Alberton V, Lococo B, Recalde C, Fazini B, : Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant 32: 13381344, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 65.

    De Rosa M, Azzato F, Toblli JE, De Rosa G, Fuentes F, Nagaraja HN, : A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int 94: 788794, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 66.

    Turner-Stokes T, Wilson HR, Morreale M, Nunes A, Cairns T, Cook HT, : Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy. Kidney Int 92: 12231231, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 67.

    Sethi S, Madden BJ, Debiec H, Charlesworth MC, Gross L, Ravindran A, : Exostosin 1/exostosin 2-associated membranous nephropathy. J Am Soc Nephrol 30: 11231136, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 68.

    Mackay M, Dall’Era M, Fishbein J, Kalunian K, Lesser M, Sanchez-Guerrero J, : Establishing surrogate kidney end points for lupus nephritis clinical trials: Development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheumatol 71: 411419, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 69.

    Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, : Multitarget therapy for induction treatment of lupus nephritis: A randomized trial. Ann Intern Med 162: 1826, 2015 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 70.

    Zhang H, Liu Z, Zhou M, Liu Z, Chen J, Xing C, : Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol 28: 36713678, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 71.

    Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, ; AURA-LV Study Group: A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 95: 219231, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 72.

    Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, : Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72: 12801286, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 73.

    Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, ; LUNAR Investigator Group: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis Rheum 64: 12151226, 2012 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 74.

    Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall’Era M, : Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol 13: 15021509, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 75.

    Chavarot N, Verhelst D, Pardon A, Caudwell V, Mercadal L, Sacchi A, ; Groupe Coopératif sur le Lupus Rénal: Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. Medicine (Baltimore) 96: e7429, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 76.

    Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, : The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun 91: 4554, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 138 138 138
Full Text Views 211 211 211
PDF Downloads 108 108 108